Radka SF[Author] - Search Results

Year	Number of Results
1977	1
1979	1
1982	1
1983	1
1984	3
1985	2
1986	3
1987	5
1988	1
1989	5
1990	2
1991	2
1992	2
1993	2
1994	3
1995	3
1996	1
2002	1
2005	1
2021	0

1

SFR3-DR5, a monoclonal antibody with HLA-DR5 specificity.

Radka SF, Machamer C, Cresswell P, Kostyu DD, Ward FE, Amos DB. Radka SF, et al. J Immunol. 1983 Apr;130(4):1863-6. J Immunol. 1983. PMID: 6187822

2

A monoclonal antibody directed against the HLA-Bw6 epitope.

Radka SF, Kostyu DD, Amos DB. Radka SF, et al. J Immunol. 1982 Jun;128(6):2804-6. J Immunol. 1982. PMID: 6176653

3

HLA-DQw3-related determinants: analysis of subunit and spatial relationships.

Radka SF, Nelson KA, Johnston JV. Radka SF, et al. Hum Immunol. 1989 Aug;25(4):225-36. doi: 10.1016/0198-8859(89)90085-2. Hum Immunol. 1989. PMID: 2475476

4

Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma.

Cai J, Gill PS, Masood R, Chandrasoma P, Jung B, Law RE, Radka SF. Cai J, et al. Among authors: radka sf. Am J Pathol. 1994 Jul;145(1):74-9. Am J Pathol. 1994. PMID: 8030759 Free PMC article.

5

Detection of mycoplasma contamination lymphoblastoid cell lines by monoclonal antibodies.

Radka SF, Hester DM, Polak-Vogelzang AA, Bolhuis RL. Radka SF, et al. Hum Immunol. 1984 Feb;9(2):111-6. doi: 10.1016/0198-8859(84)90033-8. Hum Immunol. 1984. PMID: 6698819

6

Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells.

Miles SA, Martínez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, Radka SF, Linsley PS. Miles SA, et al. Among authors: radka sf. Science. 1992 Mar 13;255(5050):1432-4. doi: 10.1126/science.1542793. Science. 1992. PMID: 1542793

7

Abrogation of the antiproliferative activity of oncostatin M by a monoclonal antibody.

Radka SF, Naemura JR, Shoyab M. Radka SF, et al. Cytokine. 1992 May;4(3):221-6. doi: 10.1016/1043-4666(92)90059-z. Cytokine. 1992. PMID: 1379836

8

Purification and identification of brain-derived neurotrophic factor from human serum.

Rosenfeld RD, Zeni L, Haniu M, Talvenheimo J, Radka SF, Bennett L, Miller JA, Welcher AA. Rosenfeld RD, et al. Among authors: radka sf. Protein Expr Purif. 1995 Aug;6(4):465-71. doi: 10.1006/prep.1995.1062. Protein Expr Purif. 1995. PMID: 8527932

9

Class II molecules of the major histocompatibility complex considered as differentiation markers.

Radka SF, Charron DJ, Brodsky FM. Radka SF, et al. Hum Immunol. 1986 Aug;16(4):390-400. doi: 10.1016/0198-8859(86)90065-0. Hum Immunol. 1986. PMID: 2428784 Review. No abstract available.

10

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC. Weng DE, et al. Among authors: radka sf. Mol Cancer Ther. 2005 Jun;4(6):948-55. doi: 10.1158/1535-7163.MCT-04-0210. Mol Cancer Ther. 2005. PMID: 15956252 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results